Châtillon, France, June 5, 2026
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) (the "Company"), a late-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 9:20 AM ET, in Miami, FL.
A live webcast of the fireside chat can be accessed here (https://event.webcasts.com/starthere.jsp?ei=1765047&tp_key=3aec5b9316&tp_specia
l=8), and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-overview/events/ (https://www.globenewswire.com/Tracker?data=MWzPeig1IXGWpY3TdHaLS2DCR-
FOzho5066yjSYubkEtBNiZsj58iWgXBc6cygmiOy75llBNRbRXPL81PLP_gQiLyP2LTnE_Sb0tXcMtib
3qM_WHQdKTu1UNQISgU0AgJ7oBZIEHKh1hk6HKVKRiTmrZyCiPXRyBqR5UpjhNymm8hYU2m3OqlIHHxg
pnuJT_), with an archived replay accessible for 90 days following the event.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment
options for food allergies and other immunologic conditions with significant
unmet medical need. DBV Technologies is currently focused on investigating the
use of its proprietary VIASKIN® patch technology to address food allergies,
which are caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening anaphylaxis.
Millions of people live with food allergies, including young children. Through
epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce
microgram amounts of a biologically active compound to the immune system through
intact skin. EPIT is a new class of non-invasive treatment that seeks to modify
an individual's underlying allergy by re-educating the immune system to become
desensitized to allergen by leveraging the skin's immune tolerizing properties.
DBV Technologies is committed to transforming the care of food allergic people.
The Company's food allergy programs include ongoing clinical trials of VIASKIN
Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4
through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT
- CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com (https://protect.checkpoint.com/v2/r01/___http://www.dbv-
technologies.com/___.YXAzOmRidi10ZWNobm9sb2dpZXM6YzpvOmE1NjczMzZmNDgwNGMwMWYxMTJ
iZDdiOGEzNDA4OWEwOjc6YTk1Njo0MTA0ZDdhNmEzZjI3MjU5MGE3YjQwMmVmNjI1NGE0MDJiZGY5ZjU
zMDBhMmE1ZTYzZGM4ZDdkOTYyN2U3NWI0OnA6VDpG) and engage with us on X (formerly Twitter)
(https://protect.checkpoint.com/v2/r01/___https://twitter.com/DBVTechnologies___
.YXAzOmRidi10ZWNobm9sb2dpZXM6YzpvOmE1NjczMzZmNDgwNGMwMWYxMTJiZDdiOGEzNDA4OWEwOjc
6MWNkZTo0MTQyM2UwZTIyMDg3ZjM4ZjY0YWM2ZDNkZTBkMzEwNzJhYWY5OGJiZWI1N2M3M2MwNjkwZTZ
lOTcxY2RiMjVhOnA6VDpG) and LinkedIn (https://protect.checkpoint.com/v2/r01/___https://www.linkedin.com/company/dbv-
technologies/___.YXAzOmRidi10ZWNobm9sb2dpZXM6YzpvOmE1NjczMzZmNDgwNGMwMWYxMTJiZDd
iOGEzNDA4OWEwOjc6MGViYTo1NDQ2ZGFjYmVlNzY5N2VlY2FmY2E2MTNkMTQ3NGQxMGZjODZjZjVmMzk
wMWVmZTkxNGM5OTA4OWU5MTcyOWVkOnA6VDpG).
VIASKIN is a registered trademark of DBV Technologies.
Investor Relations Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com (mailto:jonathan.neely@dbv-technologies.com)
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com (mailto:brett.whelan@dbv-technologies.com)
Â